Publications by authors named "David Garcia-Gomez"
Article Synopsis
- Modulation of the CXCL12-CXCR4 signaling axis is crucial for understanding its role in diseases like cancer and inflammation, with motixafortide being a leading drug that shows promise in treating various cancers.
- Despite its potential, the exact mechanism of how motixafortide interacts with the CXCR4 receptor remains unclear, prompting a study using computational techniques to analyze this relationship.
- The findings reveal that motixafortide stabilizes inactive states of CXCR4 through specific interactions between its cationic residues and CXCR4's acidic residues, providing insights for the future design of effective CXCR4 inhibitors.
Interacting binding insights and conformational consequences of the differential activity of cannabidiol with two endocannabinoid-activated G-protein-coupled receptors.
Eliud Morales Dávila Felipe Patricio Mariana Rebolledo-Bustillo David Garcia-Gomez Juan Carlos Garcia Hernandez
Front Pharmacol
August 2022
Cannabidiol (CBD), the major non-psychoactive phytocannabinoid present in the plant has displayed beneficial pharmacological effects in the treatment of several neurological disorders including, epilepsy, Parkinson's disease, and Alzheimer's disease. In particular, CBD is able to modulate different receptors in the endocannabinoid system, some of which belong to the family of G-protein-coupled receptors (GPCRs). Notably, while CBD is able to antagonize some GPCRs in the endocannabinoid system, it also seems to activate others.
View Article and Find Full Text PDF